Conference: Meeting on the Med, 2022


Precision will be at this year’s Meeting on the Med conference from April 20 – 22nd in Barcelona, Spain. Connect with our team of experts as they lead meaningful discussions throughout this event, providing insights into the clinical development, manufacturing, and commercialization of cell and gene therapies.


On-Demand Webinar: Planning for the Commercialization of Advanced Therapies


In January, the Alliance for Regenerative Medicine (ARM) released its State of the Industry Briefing which highlighted a record-breaking year for 2021. $23.1B raised for the advanced medicines sector (a 16% increase from 2020), 2,261 ongoing regenerative medicine clinical trials globally, and the evolution from treating and curing rare monogenetic diseases to more prevalent indications. Could we see 10-20 approvals each year by 2025?


On-demand Webinar- 2022 and Beyond: How Key Legislative Events will impact the payer landscape


A number of legislative events are shaping the managed care landscape in 2022. These events range from broad reaching initiatives outlined in Biden’s Build Back Better Framework to proposals for promoting adoption of biosimilars to Medicare’s Advance Notice for the 2023 benefit year and discussions around Part D re-design as well as others.


World EPA Congress 2022


Attending World EPA Congress March 22-24 in Amsterdam? Don’t miss PRECISIONadvisors Richard Macaulay and David Carr present “Gene Therapies Market Access: Lessons From The Past, Future Best Practice” March 23 at 11:45 CET, and be sure to stop by our booth to speak with one of our experts.


Conference: Gene Therapy for Rare Disorders, 2022


Precision will be at this year’s Gene Therapy for Rare Disorders from March 7 – 10th in Boston. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of therapies for rare genetic disorders.


On-Demand Webinar – Global Market Access: The Year Ahead


As we emerge from another surge in coronavirus cases, there is good reason to believe we are starting 2022 in a better position than we were this time last year.  Yet uncertainty remains. COVID-19 will have a lasting effect on healthcare budgets, as well as in areas such as clinical trials, regulatory processes and reimbursement timelines. At the same time, we are at the cusp of another wave of innovation, with a raft of new treatment modalities due to launch in the coming 12 months.


On-Demand Webinar: Cost-Effectiveness Analysis with R? A Discussion


Are you involved in preparing health technology assessment (HTA) submissions and in early health economic modeling as part of drug development decision-making? You won’t want to miss our webinar, “Cost-Effectiveness Analysis with R? A Discussion.” Learn about the pros and cons of R versus Excel in preparing HTA submissions, and the acceptability of R by HTA agencies.


Load More Posts